M28 Capital Management LP
CIK 1807489 · View on SEC EDGAR ↗
- Portfolio value
- $47.2M
- Positions
- 9
- As of
- June 30, 2026
Portfolio value QoQ: -12.3% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 8
- Effective number of positions
- 2.7
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.0% Est. buys $0 · sells $0
Median holding: 7.0 quarters Tracked Q4 2024–Q2 2026 · 81.8% still held
- New positions
- 0
- Increased
- 0
- Decreased
- 0
- Closed
- 2
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: -24.1% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.7% · Options excluded: 0.0%
Sector breakdown
Full portfolio 9 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences Ltd. - Ordinary Shares | $26,657,930 | 56.53% | 4,588,284 | $-6,607,129 | |||
| IVVD Invivyd, Inc. - Common Stock | $8,068,173 | 17.11% | 9,248,250 | $-3,954,552 | |||
| TGTX TG Therapeutics, Inc. - Common Stock | $4,854,169 | 10.29% | 88,354 | $1,919,049 | |||
| ARWR Arrowhead Pharmaceuticals, Inc. - Common Stock | $3,003,725 | 6.37% | 36,851 | $693,167 | |||
| GUTS Fractyl Health, Inc. - Common Stock | $1,474,499 | 3.13% | 1,856,117 | $624,769 | |||
| PRQR ProQR Therapeutics N.V. - Ordinary Shares | $1,115,615 | 2.37% | 599,793 | $143,950 | |||
| SLN Silence Therapeutics Plc - American Depository Share | $1,111,209 | 2.36% | 101,203 | $577,869 | |||
| RCKT Rocket Pharmaceuticals, Inc. - Common Stock | $721,179 | 1.53% | 210,871 | $-33,739 | |||
| CRIS Curis, Inc. - Common Stock | $148,741 | 0.32% | 284,889 | $-7,179 | |||
| No matches | |||||||
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| WVE | Price move only | +0 | -$6.6M |
| IVVD | Price move only | +0 | -$4.0M |
| TGTX | Price move only | +0 | +$1.9M |
| ARWR | Price move only | +0 | +$693K |
| GUTS | Price move only | +0 | +$625K |
| SLN | Price move only | +0 | +$578K |
| PRQR | Price move only | +0 | +$144K |
| RCKT | Price move only | +0 | -$34K |
| CRIS | Price move only | +0 | -$7K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| BBIO | June 30, 2025 | 121,200 | $4,189,884 | 91.4% |
| SWTX | June 30, 2025 | 55,200 | $2,435,976 | No longer tracked |